NASH

[Journal of Cellular Physiology] The authors discuss current knowledge about the biogenesis of exosomal miRNA and exosome-mediated microRNA transfer and review the potential of exosomal miRNA in diagnosis and therapeutics of nonalcoholic fatty liver disease.

[NorthSea Therapeutics B.V.] NorthSea Therapeutics B.V. announced it has initiated a Phase I study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of intestinal failure associated liver disease.

[Nature Communications] Formyl peptide receptor 2 (FPR2) was more highly expressed in hepatocytes and healthy livers from females than males, and FPR2 deletion exacerbated liver damage in choline-deficient, L-amino acid-defined, high-fat diet-fed female mice.

[Nature Metabolism] Using a candidate gene approach, researchers identified a locus at the Pleckstrin and Sec7 domain-containing 3 (PSD3) gene resulting in a leucine to threonine substitution at position 186 of the protein that reduced susceptibility to the entire spectrum of fatty liver disease in individuals at risk.

[Acta Pharmacologica Sinica] Mitochondrial dysfunction and damage induced by overnutrition lead to oxidative stress, inflammation, liver cell death, and collagen production, which advance hepatic steatosis to nonalcoholic steatohepatitis (NASH).

[Hepatology] The therapeutic efficacy and the molecular pathways targeted by TVB3664, either alone or with tyrosine kinase inhibitors or the checkpoint inhibitor anti-PD-L1 antibody, were assessed in human HCC cell lines and multiple oncogene-driven HCC mouse models.